Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy
Safety outcomes, including hospitalization rates, were similar in this first-in-human study following tarlatamab 10 mg Q2W administration with 6-8-h outpatient versus 48-h inpatient monitoring in cycle 1.
Authors
- Rafał Stec (ORCID: https://orcid.org/0000-0002-3291-6422)
- Jennifer W. Carlisle (ORCID: https://orcid.org/0000-0001-7085-4640)
- Shirish M. Gadgeel (ORCID: https://orcid.org/0000-0001-5240-3811)
- Andrew Parkes (ORCID: https://orcid.org/0000-0002-3097-0644)
- Herbert H. Loong (ORCID: https://orcid.org/0000-0002-6607-1106)
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- A. Hamidi (ORCID: https://orcid.org/0000-0003-1544-8935)
- Neeltje Steeghs (ORCID: https://orcid.org/0000-0003-2989-2279)
- Weiguo Jiang (ORCID: https://orcid.org/0000-0002-1352-1046)
- A. C. Chiang (ORCID: https://orcid.org/0000-0001-6084-1360)
- L. Paz-Ares
- Noemı́ Reguart (ORCID: https://orcid.org/0000-0001-8190-499X)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Philipp J. Jost (ORCID: https://orcid.org/0000-0003-2454-0362)
- M.E. Olmedo García
Institutions
- Hebron University (PS)
- Amgen (United States) (US)
- Emory University (US)
- Henry Ford Health System (US)
- Chinese University of Hong Kong (HK)
- Medical University of Graz (AT)
- Instituto Cajal (ES)
- Yale Cancer Center (US)
- Henry Ford Hospital (US)
- The Netherlands Cancer Institute (NL)
- Yale University (US)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Clínic de Barcelona (ES)
- University Hospitals Seidman Cancer Center (US)
- Vall d'Hebron Hospital Universitari (ES)
- Józef Piłsudski University of Physical Education in Warsaw (PL)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104538
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Amgen